Literature DB >> 19065133

Is it safe to use statins in patients with myasthenia gravis?

Nils Erik Gilhus1.   

Abstract

This Practice Point commentary discusses a retrospective study by Oh et al. in which the consequences of using statins in patients with myasthenia gravis (MG) were examined. Out of 170 patients with MG seen at a single hospital center during a 2.5-year period, 54 used statins. Six of these patients reported a worsening of MG symptoms within 8 weeks after receiving statins; in two cases the worsening was associated with a confirmed increase in serum acetylcholine receptor antibody concentration. A further seven patients retrospectively reported temporary muscle aching during the first 8 weeks after statin treatment. This effect was less clearly attributable to the drugs. The effects of statins on MG symptoms were believed to be mediated by the immune system. Statins should be used for the same indications in patients with MG as in those without the condition. However, patients with MG should be informed about the possibility of MG exacerbation, and the statins should be withdrawn if this occurs.

Entities:  

Year:  2008        PMID: 19065133     DOI: 10.1038/ncpneuro0988

Source DB:  PubMed          Journal:  Nat Clin Pract Neurol        ISSN: 1745-834X


  8 in total

Review 1.  The role of T helper cells in neuroprotection and regeneration.

Authors:  Sven Hendrix; Robert Nitsch
Journal:  J Neuroimmunol       Date:  2007-01-02       Impact factor: 3.478

Review 2.  Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review.

Authors:  B Noël
Journal:  J Eur Acad Dermatol Venereol       Date:  2007-01       Impact factor: 6.166

3.  Statins induce regulatory T cell recruitment via a CCL1 dependent pathway.

Authors:  Emilia Mira; Beatriz León; Domingo F Barber; Sonia Jiménez-Baranda; Iñigo Goya; Luis Almonacid; Gabriel Márquez; Angel Zaballos; Carlos Martínez-A; Jens V Stein; Carlos Ardavín; Santos Mañes
Journal:  J Immunol       Date:  2008-09-01       Impact factor: 5.422

Review 4.  More evidence for the association between statins and myasthenia gravis.

Authors:  Eduardo de Sousa; James Howard
Journal:  Muscle Nerve       Date:  2008-09       Impact factor: 3.217

5.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.

Authors:  C Baigent; A Keech; P M Kearney; L Blackwell; G Buck; C Pollicino; A Kirby; T Sourjina; R Peto; R Collins; R Simes
Journal:  Lancet       Date:  2005-09-27       Impact factor: 79.321

Review 6.  The molecular basis of vulnerable plaque: potential therapeutic role for immunomodulation.

Authors:  Robert L Wilensky; Damir Hamamdzic
Journal:  Curr Opin Cardiol       Date:  2007-11       Impact factor: 2.161

7.  Prevalence of musculoskeletal pain and statin use.

Authors:  Catherine Buettner; Roger B Davis; Suzanne G Leveille; Murray A Mittleman; Kenneth J Mukamal
Journal:  J Gen Intern Med       Date:  2008-05-01       Impact factor: 5.128

8.  Statins may aggravate myasthenia gravis.

Authors:  Shin J Oh; Rohit Dhall; Angela Young; Marla B Morgan; Liang Lu; Gwendolyn C Claussen
Journal:  Muscle Nerve       Date:  2008-09       Impact factor: 3.217

  8 in total
  2 in total

1.  Statins and myotoxic effects associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase autoantibodies: an observational study in Japan.

Authors:  Yurika Watanabe; Shigeaki Suzuki; Hiroaki Nishimura; Ken-Ya Murata; Takashi Kurashige; Masamichi Ikawa; Masaru Asahi; Hirofumi Konishi; Satsuki Mitsuma; Satoshi Kawabata; Norihiro Suzuki; Ichizo Nishino
Journal:  Medicine (Baltimore)       Date:  2015-01       Impact factor: 1.889

Review 2.  Statins Neuromuscular Adverse Effects.

Authors:  Silvia Attardo; Olimpia Musumeci; Daniele Velardo; Antonio Toscano
Journal:  Int J Mol Sci       Date:  2022-07-28       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.